NeoLAB Solid Tumor Monitor and BTK Inhibitor Acquired Resistance Test
NeoGenomics has launched the NeoLAB Solid Tumor Monitor and NeoLAB Bruton Tyrosine Kinase (BTK) Inhibitor Acquired Resistance test. Each new test uses cell-free DNA from peripheral blood plasma to quantify and track genomic abnormalities in the tumors of cancer patients. Resistance to BTK inhibitors is associated with mutations in the BTK and PLCG2 genes. The test is capable of detecting mutations in these two genes prior to tissue or cell-based testing. The test can be used to monitor patients treated with BTK inhibitors, especially in chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma, and to alert physicians to mutations in BTK and PLCG2 that may indicate early resistance to BTK inhibitor treatment.